A Phase 3 interventional study of PCV21 and 20vPCV in Pneumococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 38 sites in 4 countries. Open to participants aged 7 Months to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 5th largest by enrollment, is the only one that started in 2025, is one of 9 in phase 3, and was the 9th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 7 Months to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2025.
This study's enrollment of 1,268 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
Sanofi has 7 studies filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).
The duration of each participation will be approximately 9 to 11 months for each infant participant, 8 to 9 months for each toddler participant, and 6 months for each child/adolescent participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
AGE
TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS
For infants (7 to 11 MoA) and toddlers (12 to 23 MoA) only
SEX, /BARRIER METHOD AND PREGNANCY TESTING REQUIREMENTS For adolescents (6 to 17 YoA) only
OTHER INCLUSIONS
Exclusion Criteria:
MEDICAL CONDITIONS
For infants (7 to 11 MoA) and toddlers (12 to 23 MoA) only
For children (2 to 5 YoA) and adolescents (6 to 17 YoA) only
For adolescents (6 to 17 YoA) only
PRIOR/CONCOMITANT THERAPY
For children (2 to 5 YoA) and adolescents (6 to 17 YoA) only
PRIOR/CONCURRENT CLINICAL STUDY EXPERIENCE
OTHER EXCLUSIONS For adolescents (6 to 17 YoA) only
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 3 intramuscular injections of pneumococcal vaccine with an interval of: * 4 to 8 weeks (28 to 56 days) between the 1st dose and the 2nd dose * 8 to 12 weeks (56 to 84 days) between the 2nd dose and the 3rd dose AND age ≥ 12 MoA at 3rd dose
Biological: PCV21 · Biological: 20vPCV
Participants will receive 2 intramuscular injections of the pneumococcal vaccine with an interval of 8 to 12 weeks (56 to 84 days) between doses
Biological: PCV21 · Biological: 20vPCV
Participants will receive 1 intramuscular injection of the pneumococcal vaccine
Biological: PCV21 · Biological: 20vPCV
Investigational pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
Number of participants reporting immediate adverse events (AEs)
Unsolicited (spontaneously reported) systemic AEs after each and any injection of a pneumococcal vaccine
Time frame: Within 30 minutes post-vaccination
Number of participants reporting solicited injection site and solicited systemic reactions
Time frame: Up to Day 7 post-vaccination
Number of participants reporting unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs after each and any injection of a pneumococcal vaccine
Time frame: Within 30 days after vaccination
Number of participants reporting serious adverse events (SAEs) and adverse events of special interest (AESIs)
SAEs and AESIs are collected throughout the study period
Time frame: From day 0 to day 517
Number of Infants (7-11 months of age [MoA]) and toddlers (12-23 MoA): with serotype-specific IgG concentrations for all serotypes included in PCV21
Ab (antibody) concentrations for each pneumococcal serotype are measured.
Time frame: On day 30 after last vaccination
Number of Children (2-5 years of age [YoA]):with serotype specific OPA titers for all serotypes included in PCV21
Serotype specific OPA titers for each pneumococcal serotype are determined.
Time frame: On day 30
Number of Children (2-5 years of age [YoA]):with serotype specific IgG concentrations for all serotypes included in PCV21
Ab concentrations for each pneumococcal serotype are measured.
Time frame: On day 30
Number of Children/adolescents (6-17 YoA):with serotype specific OPA titers for all serotypes included in PCV21
Serotype specific OPA titers for each pneumococcal serotype are determined.
Time frame: On day 30
Number of Children/adolescents (≥ 2 YoA) with serotype specific OPA titers for all serotypes included in PCV 21
Serotype specific OPA titers for each pneumococcal serotype are determined.
Time frame: On day 30
Number of Children/adolescents (≥ 2 YoA): with serotype specific IgG concentrations for all serotypes included in PCV21
Ab concentrations for each pneumococcal serotype are measured.
Time frame: On day 30
Number of participants (all age groups) with serotype specific IgG concentration ≥ 0.35 μg/mL for all serotypes included in PCV21
Ab concentrations for each pneumococcal serotype are measured.
Time frame: On day 30 after last vaccination
Number of infants (7-11 MoA) and toddlers(12-23 MoA):with serotype specific OPA titers for all serotypes included in PCV21
Serotype specific OPA titers for each pneumococcal serotype are determined.
Time frame: On day 30 after last vaccination
Percentage of infants (7-11 MoA) and toddlers(12-23 MoA): with serotype specific OPA titers ≥ LLOQ for all serotypes included in PCV21
Serotype specific OPA titers for each pneumococcal serotype included in the PCV21 formulations are determined. The following threshold values will be considered: ≥ lower limit of quantitation (LLOQ)
Time frame: On day 30 after last vaccination
Number of Children/adolescents (6-17 YoA):with serotype specific IgG concentrations for all serotypes included in PCV21
Ab concentrations for each pneumococcal serotype are measured.
Time frame: On day 30
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 21 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine
Sanofi Pasteur, a Sanofi Company →